Delisting risk
CVM · AMEX · Biotechnology

CEL-SCI

Develops a pre-surgical cytokine treatment for selected head-and-neck cancer patients.

$1.63
After-hours close+0.06 (+4.17%)
At close$1.56(−2.50%)
DateEstimateReportedSurprise
Aug 2026−$0.47
May 2026−$0.67
Feb 2026−$0.68
Jan 2026−$2.70

The latest year is open to everyone — the 42 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Feb 2025
Jan 2025
Aug 2024
May 2024
Feb 2024
Dec 2023
Aug 2023
May 2023
Feb 2023
Dec 2022
Aug 2022
May 2022
Feb 2022
Dec 2021
Aug 2021
May 2021
Feb 2021
Dec 2020
Aug 2020
May 2020
Feb 2020
Dec 2019
Aug 2019
May 2019
Feb 2019
Dec 2018
Aug 2018
May 2018
Feb 2018
Dec 2017
Aug 2017
May 2017
Feb 2017
Dec 2016
Aug 2016
May 2016
Feb 2016
Dec 2015
Aug 2015
May 2015
Report dateEPS estEPSSurpriseRevenue estRevenueSurprise
Aug 14, 2026−$0.47
May 18, 2026−$0.67
Feb 17, 2026−$0.68
Jan 12, 2026−$2.70

The latest year is open to everyone — the 42 quarters behind it read with an account.

Sign in
Aug 14, 2025
May 14, 2025
Feb 14, 2025
Jan 13, 2025
Aug 14, 2024
May 16, 2024
Feb 14, 2024
Dec 22, 2023
Aug 11, 2023
May 12, 2023
Feb 14, 2023
Dec 28, 2022
Aug 15, 2022
May 16, 2022
Feb 14, 2022
Dec 22, 2021
Aug 16, 2021
May 18, 2021
Feb 16, 2021
Dec 30, 2020
Aug 11, 2020
May 11, 2020
Feb 10, 2020
Dec 16, 2019
Aug 14, 2019
May 14, 2019
Feb 14, 2019
Dec 20, 2018
Aug 14, 2018
May 15, 2018
Feb 12, 2018
Dec 29, 2017
Aug 9, 2017
May 10, 2017
Feb 9, 2017
Dec 14, 2016
Aug 10, 2016
May 10, 2016
Feb 9, 2016
Dec 11, 2015
Aug 7, 2015
May 8, 2015